ReviewEnzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug
Introduction
Currently much attention is being focused on the interaction of small molecules with biological macromolecules. The search for selective enzyme inhibitors and receptor agonists/antagonists is key for target-oriented research in the pharmaceutical and agrochemical industries. Increased understanding of the mechanism of drug interactions on a molecular level has led to a strong awareness of the importance of chirality as the key to the efficacy of many drug products and agrochemicals. The production of optically active chiral intermediates is a subject of increasing importance in the pharmaceutical industry. Increasing regulatory pressure to market homochiral drugs [1], [2] has led to the use of chemical or chemo-enzymatic synthesis of chiral compounds. The advantages of biocatalysis over chemical catalysis are that enzyme-catalyzed reactions are often highly stereoselective and regioselective and can be carried out at ambient temperature and atmospheric pressure, thus by avoiding extreme conditions one can minimize problems of isomerization, racemization, epimerization, and rearrangements that may occur during typical chemical processes. Biocatalytic processes catalyzed by microbial cells and enzymes derived therefrom can be immobilized and reused for many cycles. In addition, enzymes can be overexpressed to make biocatalytic processes economically efficient. The idea of designing biocatalysts that would act specifically in any desired reaction of interest will change the face of synthesis. Tailor-made enzymes with modified activity and the preparation of thermostable and pH stable enzymes produced by random and site-directed mutagenesis have lead to the production of novel stereoselective biocatalysts. The use of enzymes in organic solvents has led to hundreds of publications on enzyme-catalyzed asymmetric synthesis and resolution processes. Molecular recognition and selective catalysis are key chemical processes in life which are embodied in enzymes. A number of review articles [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18] have been published on the use of biocatalysis in organic synthesis. This chapter provides different approaches towards the use of microbial enzymes for the synthesis of chiral intermediates for Omapatrilat 1 (Fig. 1) by three different routes. Omapatrilat 1 is an antihypertensive drug which acts by inhibiting angiotensin-converting enzyme (ACE) and neutral endopeptidase [19]. ACE a zinc-containing carbopeptidase, catalyzes the conversion of the decapeptide angiotensin I (AI) to the octapeptide angiotensin II (AII). AII is a potent vasoconstrictor which also triggers the release of aldosterone, a sodium-retaining steroid. Thus ACE raises blood pressure by increasing both vascular resistance and fluid volume. Effective inhibitors of ACE have been used not only in the treatment of hypertension but in the clinical management of congestive heart failure [20]. Neutral endopeptidase (NEP), like ACE, is a zinc metalloprotease and is found in high concentration in the brush border of the renal proximal tubule. NEP is highly efficient in degrading atrial natriuretic peptide (ANP), a 28-amino acid peptide secreted by the heart in response to atrial distension. ANP has opposing hormonal actions to those of AII. By interaction with its receptor, ANP promotes the generation of cGMP via guanylate cyclase activation, thus resulting in vasodilatation, natriuresis, diuresis, and inhibition of aldosterone [21]. Therefore simultaneous potentiation of ANP via NEP inhibition and attenuation of AII via ACE inhibition should lead to complementary effects in the management of hypertension and congestive heart failure [22], [23].
Section snippets
Synthesis of key intermediates for omapatrilat
The enzymatic and/or microbial synthesis of single enantiomers of three chiral intermediates by three different routes to Omapatrilat 1 were developed as described below.
Conclusion
The production of optically active chiral intermediates is a subject of increasing importance to the pharmaceutical industry. Increasing regulatory pressure to market homochiral drugs [1], [2] has led to the use of alternative approaches, including biocatalysis for the synthesis of chiral compounds. Organic synthesis has been one of the most successful scientific disciplines and has enormous practical utility. One can ask question then why biocatalysis? What has biocatalysis to offer to
Acknowledgements
The author would like to acknowledge Drs Ronald Hanson, Amit Banerjee, Venkata Nanduri, Jeffrey Howell, Steven Goldberg, Robert Johnston, Paul Cino, Mary-Jo Donovan, Dana Cazzulino, Shanker Swaminathan, Lawrence Parker, John Venit, Thomas LaPorte, Thomas Tully, John Wasylyk, Laszlo Szarka, Michael Montana, Sushil Srivastava, Jerome Moniot and Raphael Ko for research collaboration during this work. The author would also like to acknowledge and thank Drs Richard Mueller and John Venit for their
References (50)
Tetrahedron
(1986)Tetrahedron
(1991)Enzyme Microb. Technol.
(1993)Adv. Appl. Microbiol.
(1997)- et al.
Tetrahedron Lett.
(1994) - et al.
Bioorg. Med. Chem.
(1999) - et al.
Bioorg. Med. Chem.
(1995) - et al.
Enzyme Microb. Technol.
(2000) - et al.
Arch. Biochem. Biophys.
(1982) - et al.
Methods Enzymol.
(1987)
Enzyme Microb. Technol.
Tetrahedron Asymmetry
Angew Chem. Int. Ed. Engl.
Biocatalysis
Biotechnology
Chem. Rev.
Adv. Biochem. Eng. Biotech.
Chirality
Chem. Rev.
Tetrahedron
Annu. Rev. Microbiol.
Cited by (80)
Surface display of (R)-carbonyl reductase on Escherichia coli as biocatalyst for recycling biotransformation of 2-hydroxyacetophenone
2022, Biochemical Engineering JournalCitation Excerpt :Chiral hydroxy compounds are a class of optically active modular compounds with hydroxyl groups attached to chiral carbons [1], which are widely used in medicine [2,3], pesticides [4], fine chemicals [5], functional materials [6], and other industries due to their unique optical, thermal stability, and chemical properties.
Biocatalysis for synthesis of pharmaceuticals
2018, Bioorganic and Medicinal ChemistryCitation Excerpt :Yeast formate dehydrogenase is commonly used for NADH regeneration and glucose dehydrogenase usually from Bacillus species may be used for either NADH or NADPH regeneration. There are excellent publications and reviews on the amino acid dehydrogenases and examples of their synthetic utilities.24–32 Saxagliptin 1 (Fig. 1), a DPP-IV inhibitor33–36 developed by Bristol-Myers Squibb and approved by food and drug administration for treatment of type II diabetes.
Candida parapsilosis: A versatile biocatalyst for organic oxidation-reduction reactions
2016, Bioorganic ChemistryEnzymes From Rare Actinobacterial Strains
2016, Advances in Food and Nutrition Research